



Teleflex to Focus on Patient Safety at American Association of Respiratory Care Conference

November 30, 2010

Products focus on minimizing risk and maximizing outcomes

LIMERICK, Pa., Nov 30, 2010 (BUSINESS WIRE) --

Teleflex Incorporated will showcase a number of respiratory products designed to help providers minimize risk and maximize outcomes for their patients at the annual AARC International Respiratory Congress in Las Vegas, Nevada on December 6-9, 2010.

On display will be Teleflex's suite of ventilation management solutions that are designed to promote best practices in Ventilator Associated Pneumonia (VAP) risk reduction. VAP is the most common infection acquired by adults and children in intensive care units (ICUs) and is a cause of significant patient morbidity and mortality, increased utilization of healthcare resources and excess cost.¹ Recognizing this challenge, Teleflex is committed to providing solutions that reduce infection risk and ensure the reliable execution of evidence-based medicine, including:

- **ISIS^(R) HVT(TM) Endotracheal Tube:** The ISIS HVT is the first convertible endotracheal tube, allowing for subglottic secretion removal, on demand. This versatile design eliminates the need to be selective during initial intubation, increasing the number of patients who can be viable candidates for subglottic secretion suctioning, a clinically proven strategy for VAP reduction.¹ In addition, the ISIS HVT has been proven to reduce the incidence of suction lumen clogging, a common challenge encountered by caregivers today.
- **Gibeck(R) Humid-Flo(R) Kit:** An integrated system that promotes best practices, the Gibeck Humid-Flo passive humidification kit allows all components to remain in-line during the first 72 hours of mechanical ventilation. This exclusive design allows for the consistent application of VAP risk reduction strategies.^{1,2,3}
- **ConchaTherm(R) Neptune(R):** When combined with the ResMed NIV interface, this heated humidifier works to promote patient compliance to Non Invasive Positive Pressure Ventilation (NPPV), which has been associated with higher survival rates and reduction of nosocomial infections.⁴

Teleflex is also scheduled to participate in the RC Solutions Showcase on Monday, December 6, during the congress. Jeri E Eiserman, BS, MBA, RRT, Teleflex Director of Clinical Support will present a lecture focused on respiratory solutions for reducing the risk of Ventilator Associated Pneumonia. The focus of the discussion will be on products and programs designed to help clinicians adhere to clinical practice guidelines and recommendations from the CDC, IHI, AARC and SHEA.

"Teleflex, through our comprehensive portfolio of critical care products, is dedicated to providing clinicians the tools to minimize risk and maximize outcomes," said Cary Vance, Executive Vice President, Teleflex, North America. "We are committed to working with the respiratory community as a trusted resource and partner."

To see the ISIS HVT, the Gibeck Humid-Flo Passive Humidification Kit and other Teleflex products, visit Teleflex at Booth 335 at AARC. For more information on Teleflex's respiratory and airway management products, visit www.teleflexmedical.com.

About Teleflex Incorporated

Teleflex Incorporated (NYSE: TFX) is a global provider of medical technology products that enable healthcare providers to improve patient outcomes, reduce infections and support patient and provider safety. Teleflex, which employs approximately 12,800 people worldwide, also has niche businesses that serve segments of the aerospace and commercial markets with specialty engineered products. Additional information about Teleflex can be obtained from the company's website at www.teleflex.com.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

¹ Coffin S MD, MPH, Klompas M MD, Classen D MD, et al. Strategies to Prevent Ventilator- Associated Pneumonia in Acute Care Hospitals. *Infect Control Hosp Epidemiol* 2008; 29:S31-S40.

² AARC Evidence Based Guidelines, Care of the Ventilator Circuit and Its Relation to Ventilator Associated Pneumonia. *Respiratory Care* 2003;48:875.

³ Guidelines for Preventing Hospital Associated Pneumonia: Recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee 2003

⁴ Girou E, Schortgen F, Delclaux C, et al. Association of noninvasive ventilation with nosocomial infections and survival in critically ill patients. *JAMA*. 2000;284:2361-7.

SOURCE: Teleflex Incorporated

Teleflex Incorporated

Jake Elguicze, Vice President Investor Relations, 610-948-2836